Stay updated on Omalizumab in Multi-Allergen OIT Clinical Trial
Sign up to get notified when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.

Latest updates to the Omalizumab in Multi-Allergen OIT Clinical Trial page
- ChecktodayChange DetectedPage revision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedChanged the label for the update timestamp from 'Last Update Posted (Estimated)' to 'Last Update Posted' on the study record. This alters how update times are displayed but does not affect the underlying study data or eligibility criteria.SummaryDifference0.0%

- Check22 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded a Locations section listing study sites by state (Arkansas, California, Colorado, Georgia, Maryland, Massachusetts, New York, North Carolina, Pennsylvania, Texas) and updated the revision to v3.3.3.SummaryDifference0.7%

- Check73 days agoChange DetectedPublication section updated: added language that publications are provided voluntarily by the person entering information, and the revision label updated to v3.3.2 (replacing the previous phrasing about the study results). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check80 days agoChange DetectedNotice about lapse in government funding and operating status has been removed; the page no longer provides guidance to check current status on cc.nih.gov or opm.gov.SummaryDifference0.2%

Stay in the know with updates to Omalizumab in Multi-Allergen OIT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.